|
12 Massague J. TGFbeta signal transduction. Annu Rev Biochem 1998;67:753791
13 Munir S, Xu G, Wu Y, et al. Nodal and ALK7 inhibit proliferation and induce apoptosis in human trophoblast. J Biol Chem 2004;279(30):3127731286
14 Shen W, Liu L. Expression of transforming growth factorβ trpe II receptor in rat retina. Int J Ophthalmol(Guoji Yanke Zazhi) 2008;8(6):10731075
15 Derynck R, Zhang YE. Smaddependent and Smadindependent pathways in TGFbeta family signlling. Nature 2003;425(6958):577584
16 Uhl M, Aulwurm S, Wischhusen J, et al. SD208, a novel transforming growth factorbeta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004;64(21):79547961
17 Hayashi T, Hideshima T, Nguyen AN, et al. Transforming growth factorbeta receptor I kinase inhibitor downregulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 2004;10(22):75407546
18 Bass BL. Doublestranded RNA as a template for gene silencing. Cell 2000;101(3):235238
19 Verma NK, Dey CS. RNAmediated gene silencing: mechanisms and its therapeutic applications. J Clin Pharm Ther 2004;29(5):395404
20 Shen W, Liu L. Gene expression of transforming growth factorβ2 in retina of diabetic rats. Int J Ophthalmol(Guoji Yanke Zazhi) 2008;8(6):10651069
21 Nakamura H, Siddiqui SS, Shen X, et al. RNA interference targeting transforming growth factorbeta type II receptor suppresses ocular inflammation and fibrosis. Mol Vis 2004;10:703711
22 Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002;1(5):347355
23 Marwick C. First "antisense" drug will treat CMV retinitis. JAMA 1998;280(10):871
24 Cordeiro MF, Mead A, Ali RR, et al. Novel antisense oligonucleotides targeting TGFβ inhibit in vivo scarring and improve surgical outcome. Gene Ther 2003;10(1):5971
25 Li JY, Fu P, Yang Q. Experimental study of TGFβ2 antisense digodeoxynucleotide as an antiscarring agent inglancoma surgery. Int J Ophthalmol(Guoji Yanke Zazhi) 2007;7(1):1014
26 Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factorbeta by the proteoglycan decorin. Nature 1990;346(6281):281284
27 Grisanti S, Szurman P, Warga M, et al. Decorin modulates wound healing in experimental glaucoma filtration surgery: a pilot study. Invest Ophthalmol Vis Sci 2005;46(1):191196
28 Carrington LM, Albon J, Anderson I, et al. Differential regulation of key stages in early corneal wound healing by TGFbeta isoforms and their inhibitors. Invest Ophthalmol Vis Sci 2006;47(5):18861894
29 Denton CP, Merkel PA, Furst DE, et al. Recombinant human antitransforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebocontrolled phase I/II trial of CAT192. Arthritis Rheum 2007;56(1):323333
30 Thompson JE, Vaughan TJ, Willams AJ, et al. A fully human antibody neutralizing biologlcally active human TGFβ2 for use in therapy. J Immunol Methods 1999;227(1):1729
31 Broadway DC, Migdal CS, Salmon J, et al. Adjunctive antiTGFβ2 human monoclonal antibody as a novel agent to prevent scarring following phacotrabeculectomy. Invest Ophthalmol Vis Sci 2002;43:33313333
32 Khaw P, Grehn F, Hollo G, et al. A phase III study of subconjunctival human antitransforming growth factor beta(2) monoclonal antibody (CAT152) to prevent scarring after firsttime Trabeculectomy. Ophthalmology 2007;114(10):18221830
33 Cordeiro MF, Gay JA, Khaw PT. Human antitransforming growth factorβ2 antibody: A New glaucoma antiscarring agent. Invest Ophthalmol Vis Sci 1999;40(10):22252234
34 Mead AL, Wong TT, Cordeiro MF, et al. Evaluation of antiTGFbeta2 antibody as a new postoperative antiscarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci 2003;44(8):33943401
35 Siriwardena D, Khaw PT, King AJ, et al. Human antitransforming growth factor beta(2) monoclonal antibodya new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study. Ophthalmology 2002;109(3):427431
36 GordonThomson C, De Iongh RU, Hales AM, et al. Differential cataractogenic potency of TGFbeta1, beta2, and beta3 and their expression in the postnatal rat eye. Invest Ophthalmol Vis Sci 1998;39(8):13991409
37 Saika S, Okada Y, Miyamoto T, et al. Smad translocation and growth suppression in lens epithelial cells by endogenous TGFbeta2 during wound repair. Exp Eye Res 2001;72(6):679686
38 Wormstone, IM, Tamiya S, Anderson I, et al. TGFbeta2 induced matrix modification and cell transdifferentiation in the human lens capsular bag. Invest Ophthalmol Vis Sci 2002;43(7):23012308
39 Hales AM, Schulz MW, Chamberlain CG, et al. TGFβ2 induces lens cells to accumulate αsmooth muscle actin, a marker for subcapsular cataracts. Curr Eye Res 1994;13:885890
40 Kurosaka D, Kato K, Nagamoto T, et al. Growth factors influence contractility and αsmooth muscle actin expression in bovine lens epithelial cells. Invest Ophthalmol Vis Sci 1995;36(8):17011708
41 Wormstone IM, Anderson IK, Eldred JA, et al. Shortterm exposure to transforming growth factor ( induces longterm fibrotic responses. Exp Eye Res 2006;83(5):12381245
42 Lois N, Taylor J, McKinnon AD, et al. Effect of TGFβ2 and AntiTGFβ2 antibody in a new in vivo rodent model of posterior capsule opacification. Invest Ophthal Vis Sci 2005;46(11):42604266
43 Carrington L, Mcleod D, Boultom M. IL10 and antibodies to TGFβ2 and PDGF inhibit RPEmediated retinal contraction. Invest Ophthalmol Vis Sci 2000;41(5):12101216
44 Li X, Hu Q. Regulation of TGFβ2 on the expression of Foxp3 in experimental autoimmune uveoretinitis by injected into vitreous cavity. Int J Ophthalmol(Guoji Yanke Zazhi) 2008;8(7):13561359
上一页 [1] [2] [3] [4] |
